Abstract: Disclosed are compounds of Formula (I) below and pharmaceutically acceptable salts thereof: in which each of variables MNox, L and ZBG is defined herein. Also disclosed is a method for treating a cancer with a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.

Abstract: The present invention pertains to a new derivative of ovatodiolide, which has unexpectedly good cytotoxicity in cancer cells. Also provided are the preparation process and the use of the new derivative of ovatodiolide.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), R1, R2 and R3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, C1-C6 alkoxy, carboxylic acid, C1-C6 alkoxycarbonyl, C1-C6 amino, C1-C6 aminocarbonyl, C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 heterocyclic, aryl or heteroaryl, provided at least one of R1 and R3 is an amino group. A linker-drug and a ligand-drug conjugate including the compound are also provided.

Abstract: An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided.

Abstract: Provided are benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof. Also provided is a method for treating cancer by using a pharmaceutical composition including the benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), R1, R2 and R3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, C1-C6 alkoxy, carboxylic acid, C1-C6 alkoxycarbonyl, C1-C6 amino, C1-C6 aminocarbonyl, C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 heterocyclic, aryl or heteroaryl, provided at least one of R1 and R3 is an amino group. A linker-drug and a ligand-drug conjugate including the compound are also provided.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), R1, R2 and R3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, C1-C6 alkoxy, carboxylic acid, C1-C6 alkoxycarbonyl, C1-C6 amino, C1-C6 aminocarbonyl, C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 heterocyclic, aryl or heteroaryl, provided at least one of R1 and R3 is an amino group. A linker-drug and a ligand-drug conjugate including the compound are also provided.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), R1, R2 and R3 are each, independently, hydrogen, amino, nitro, halogen, hydroxyl, C1-C6 alkoxy, carboxylic acid, C1-C6 alkoxycarbonyl, C1-C6 amino, C1-C6 aminocarbonyl, C1-C6 alkyl, branched C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 heterocyclic, aryl or heteroaryl, provided at least one of R1 and R3 is an amino group. A linker-drug and a ligand-drug conjugate including the compound are also provided.

Abstract: An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided.

Abstract: An azaazulene compound is provided. The azaazulene compound has formula (I) shown below. Each variable in formula (I) is defined in the specification. The compound can be used to treat cancer. The invention also provides a method for treating cancer. The method includes administering to a subject in need thereof an effective amount of one or more azaazulene compounds of formula (I).

Abstract: This invention relates to compounds of the following general formula: The variables are defined herein. Also disclosed is a method for treating mucositis or cancer using these compounds.

Abstract: A huperzine A compound is provided. The huperzine A compound has following formula: wherein X comprises O or S, Y comprises —O—, —S—, —CH(R4)—, —C(R4)(R5)—, —C(R4)?C(R5)—, —C?C—, —NH— or —N(R4)—, n is 0, 1 or 2, R3 is C(?X)—(Y)n—R1 provided that R2 is H or R2 and R3 are combined to form ?CH—Ar, wherein R1, R4 and R5 independently comprise hydrogen, C1-C32 alkyl, C1-C32 alkenyl, C1-C32 alkynyl, C1-C32 aryl or C1-C32 heteroaryl, in which alkyl, alkenyl, alkynyl, aryl or heteroaryl with one or more substituents comprising halogen, hydroxyl, alkoxy, aryloxyl, amino, alkylamino, arylamino, dialkylamino, diarylamino, imino, alkylimino, arylimino, acylamido, diacylamido, acylimido, cyano, nitro, mercapto, carbamido, carbamoyl, carboxyl, thioureido, thiocyanato, sulfonamido, thio, sulfonyl or sulfinyl, and Ar comprises aryl or heteroaryl.

Abstract: This invention relates to novel Histone deacetylases inhibitors. Also disclosed is a method for treating mucositis or cancer with these inhibitors.

Abstract: An azaazulene compound is provided. The azaazulene compound has formula (I) shown below. Each variable in formula (I) is defined in the specification. The compound can be used to treat cancer. The invention also provides a method for treating cancer. The method includes administering to a subject in need thereof an effective amount of one or more azaazulene compounds of formula (I).

Abstract: An incident managing module aggregates related database intrusion incidents and presents them in a manageable manner. A receiving module receives an anomalous query requesting data from a database and a type-identification module identifies anomaly type for the query received. A conversion module converts the anomalous query into a characteristic representation. In some embodiments, this is done by replacing literal field values in the query with representative values. In other embodiments, this is done by creating a tuple describing anomaly parameters for the anomalous query. In still other embodiments, the query is converted into a characteristic representation that distinguishes between injected and non-injected portions of the query. An aggregation module then aggregates into a group the anomalous queries with substantially similar characteristic representations according to anomaly type and a generation module generates a database intrusion incident report describing the group of anomalous queries.

Abstract: The invention is related to novel azulene-oxindole compounds having formula (I) shown below, wherein one of R1, R2 and R3 represents a moiety of formula (II), each of A1 and A2 independently is nitrogen, oxygen or sulfur, each of the others of R1, R2, R3, R1, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 is as recited in the specification. The novel compound potentially inhibits multiple kinases and thus can be used to treat some disease like cancer or inflammatory.

Abstract: An oligopeptide comprises formulae (I) or (II) the oligopeptide derivative thereof, and a pharmaceutical composition comprising the same are provided.

Abstract: An azulene compound is provided. The azulene compound has formula (I) shown below. Each variable in formula (I) is defined in the specification. One of R1, R2, R3, R4, R5, R6, R7, and R8 in formula (I) is a moiety of formula (II). The compound can be used to treat cancer.

Abstract: A huperzine A compound is provided. The huperzine A compound has following formula: wherein X comprises O or S, Y comprises —O—, —S—, —CH(R4)—, —C(R4)(R5)—, —C(R4)?C(R5)—, —C?C—, —NH— or —N(R4)—, n is 0, 1 or 2, R3 is C(?X)—(Y)n-R1 provided that R2 is H or R2 and R3 are combined to form ?CH—Ar, wherein R1, R4 and R5 independently comprise hydrogen, C1-C32 alkyl, C1-C32 alkenyl, C1-C32 alkynyl, C1-C32 aryl or C1-C32 heteroaryl, in which alkyl, alkenyl, alkynyl, aryl or heteroaryl with one or more substituents comprising halogen, hydroxyl, alkoxy, aryloxyl, amino, alkylamino, arylamino, dialkylamino, diarylamino, imino, alkylimino, arylimino, acylamido, diacylamido, acylimido, cyano, nitro, mercapto, carbamido, carbamoyl, carboxyl, thioureido, thiocyanato, sulfonamido, thio, sulfonyl or sulfinyl, and Ar comprises aryl or heteroaryl.

Abstract: This invention relates to a method for treating an angiogenesis-related disease. The method includes administering to a subject in need thereof an effective amount of a piperazinedione compound having the formula: In the above formula, each of and , independently, is a single bond or a double bond; A is H or CH(RaRb) when is a single bond, or C(RaRb) when is a double bond; Z is CH(RcRd) when is a single bond, or C(RcRd) when is a double bond; each of R1 and R2, independently, is H, C(O)Re, C(O)ORe, C(O)NReRf, or SO2Re; and each of Ra, Rb, Rc, Rd, Re, and Rf, independently, is H, C1-C6 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or C3-C8 heterocycloalkyl; or Ra and Rb taken together are C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, aryl, or heteroaryl; or R1 and Ra or R1 and Rb taken together are C3-C8 cycloalkyl, C3-C8 heterocycloalkyl, aryl, or heteroaryl; provided that one of Rc and Rd is aryl or heteroaryl.